Rocket Doctor’s marketing agreement with Rick Ware Racing and FINTEKK AP, signed in June, carries a contractual decision point at the end of September that has nothing to do with lap times. Unless Rocket Doctor delivers written notice at least ten days before September 30 electing to pause the arrangement, the company automatically owes its marketing partners an additional 3,000,000 shares to keep the campaign running through year end.
Vancouver-based investor Yazan Al Homsi, who holds a position in Rocket Doctor through Founders Round Capital, has argued that this notice mechanism, not the racing itself, is the part of the deal worth scrutinizing. He owns shares in the company, a position he has chosen to disclose rather than leave to assumption, and holds no board seat or operating role. More on his approach to evaluating deal structures is on his website, and his background is listed on his LinkedIn profile.
Rocket Doctor, a physician-led virtual care platform connecting doctors with patients through a digital marketplace, agreed to a marketing partnership spanning the NASCAR Cup Series, NHRA, American Flat Track and World Supercross. The company issued the marketing partners 7,000,000 common shares at a deemed price of US$0.50 each, a stated value of US$3.5 million, for services rendered from June 6 through September 30.
Whether Rocket Doctor exercises its opt-out is itself informative: a public decision either way is a data point about how the company weighs the campaign’s return against its dilution cost. Marketing partners under the deal include NASCAR Cup Series driver Cody Ware, alongside athletes competing in NHRA, American Flat Track and World Supercross.